EASL Recommendations on Treatment of Hepatitis C 2016

Watch
Summary Presentation - EASL Recommendations on Treatment of Hepatitis C 2016
Watch the livestreamed EASL updated  HCV recommendations with a follow-up Q&A session.

More on EASL HCV recommendations
The new recommendations add Epclusa (sofosbuvir/velpatasvir, Gilead Sciences) and Zepatier (grazoprevir/elbasvir, Merck) to the arsenal of treatments
​Continue reading...

EASL Recommendations on Treatment of Hepatitis C 2016

Download 2016 - Update of the HCV EASL recommendations

Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal histological changes to extensive fibrosis and cirrhosis with or without hepatocellular carcinoma (HCC).

The number of chronically infected persons worldwide is estimated to be about 180 million [2], but most are unaware of their infection. Clinical care for patients with HCV-related liver disease has advanced considerably during the last two decades, thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention.